Asia Pacific Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor),

Asia Pacific minimal residual disease (MRD) testing market will grow by 15.5% annually with a total addressable market cap of $4,575.0 million over 2022-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure. 

Highlighted with 34 tables and 54 figures, this 115-page report “Asia Pacific Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

 

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure 

• Growth Drivers 

• Restraints and Challenges

• Emerging Product Trends & Market Opportunities

• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Country. 

 

Based on Offering, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. 

• Services

• Test Kits & Consumables

 

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. 

• Non-Hodgkin's Lymphoma (NHL)

o DLBCL

o Marginal Zone Lymphoma

o Follicular Lymphoma

o Peripheral T-cell Lymphoma

o Mantle Cell Lymphoma

o Other NHLs

• Multiple Myeloma (MM)

• Acute Lymphoblastic Leukemia (ALL)

• Chronic Lymphoblastic Leukemia (CLL)

• Acute Myeloid Leukemia (AML)

• Chronic Myeloid Leukemia (CML)

• Hodgkin's Lymphoma (HL)

• Solid Tumor

• Other Applications

 

By Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. 

• Flow Cytometry

• Polymerase Chain Reaction (PCR)

• Next-Generation Sequencing (NGS)

• Other Technologies

 

By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. 

• Hospitals and Clinics

• Research Institutions

• Diagnostic Laboratories

• Other End Users

 

Geographically, the following national/local markets are fully investigated:

• Japan

• China

• South Korea

• Australia

• India

• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Technology, and End User over the forecast years are also included.

 

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players: 

Adaptive Biotechnologies Corporation

ArcherDX, Inc. (Invitae Corporation)

Arup Laboratories

Asuragen Inc.

Bio-Rad Laboratories, Inc.

Cergentis B.V.

Guardant Health

ICON plc

Inivata Ltd.

Invivoscribe, Inc.

Laboratory Corporation of America Holdings

Mission Bio, Inc.

Natera, Inc.

NeoGenomics Laboratories, Inc.

Opko Health, Inc.

Quest Diagnostics Incorporated

Sysmex Corporation 

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

 

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.1.1 Impact of COVID-19 on World Economy 20

2.1.2 Impact of COVID-19 on the Market 22

2.2 Major Growth Drivers 24

2.3 Market Restraints and Challenges 30

2.4 Emerging Opportunities and Market Trends 33

2.5 Porter’s Fiver Forces Analysis 37

3 Segmentation of Asia Pacific Market by Offering 41

3.1 Market Overview by Offering 41

3.2 Services 43

3.3 Test Kits & Consumables 44

4 Segmentation of Asia Pacific Market by Application 45

4.1 Market Overview by Application 45

4.2 Non-Hodgkin’s Lymphoma (NHL) 47

4.2.1 DLBCL 49

4.2.2 Marginal Zone Lymphoma 50

4.2.3 Follicular Lymphoma 51

4.2.4 Peripheral T-cell Lymphoma 52

4.2.5 Mantle Cell Lymphoma 53

4.2.6 Other NHLs 54

4.3 Multiple Myeloma (MM) 55

4.4 Acute Lymphoblastic Leukemia (ALL) 56

4.5 Chronic Lymphoblastic Leukemia (CLL) 57

4.6 Acute Myeloid Leukemia (AML) 58

4.7 Chronic Myeloid Leukemia (CML) 59

4.8 Hodgkin’s Lymphoma (HL) 60

4.9 Solid Tumor 61

4.10 Other Applications 62

5 Segmentation of Asia Pacific Market by Technology 63

5.1 Market Overview by Technology 63

5.2 Flow Cytometry 65

5.3 Polymerase Chain Reaction (PCR) 66

5.4 Next-Generation Sequencing (NGS) 67

5.5 Other Technologies 68

6 Segmentation of Asia Pacific Market by End User 69

6.1 Market Overview by End User 69

6.2 Hospitals and Clinics 71

6.3 Research Institutions 72

6.4 Diagnostic Laboratories 73

6.5 Other End Users 74

7 Asia-Pacific Market 2021-2031 by Country 75

7.1 Overview of Asia-Pacific Market 75

7.2 Japan 78

7.3 China 81

7.4 Australia 83

7.5 India 86

7.6 South Korea 88

7.7 Rest of APAC Region 90

8 Competitive Landscape 92

8.1 Overview of Key Vendors 92

8.2 New Product Launch, Partnership, Investment, and M&A 96

8.3 Company Profiles 97

Adaptive Biotechnologies Corporation 97

ArcherDX, Inc. (Invitae Corporation) 99

Arup Laboratories 100

Asuragen Inc. 101

Bio-Rad Laboratories, Inc. 102

Cergentis B.V. 103

Guardant Health 104

ICON plc 105

Inivata Ltd. 106

Invivoscribe, Inc. 107

Laboratory Corporation of America Holdings 108

Mission Bio, Inc. 109

Natera, Inc. 110

NeoGenomics Laboratories, Inc. 111

Opko Health, Inc. 112

Quest Diagnostics Incorporated 113

Sysmex Corporation 114

RELATED REPORTS 115

 

List of Tables:

 

Table 1.  Snapshot of Asia Pacific Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031 17

Table 2. World Economic Outlook, 2021-2031 21

Table 3. World Health Spending by Region, $ bn, 2013-2020 29

Table 4.  Main Product Trends and Market Opportunities in Asia Pacific Minimal Residual Disease Testing Market 33

Table 5. Asia Pacific Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn 41

Table 6. Asia Pacific Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 45

Table 7. Asia Pacific Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn 48

Table 8. Asia Pacific Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 63

Table 9. Main Vendors and Products of Flow Cytometry Technology 65

Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology 66

Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology 67

Table 12. Asia Pacific Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 69

Table 13. APAC Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn 76

Table 14. Japan Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 80

Table 15. Japan Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 80

Table 16. Japan Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 80

Table 17. China Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 82

Table 18. China Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 82

Table 19. China Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 82

Table 20. Australia Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 85

Table 21. Australia Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 85

Table 22. Australia Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 85

Table 23. India Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 87

Table 24. India Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 87

Table 25. India Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 87

Table 26. South Korea Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn 89

Table 27. South Korea Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn 89

Table 28. South Korea Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn 89

Table 29. Minimal Residual Disease Testing Market in Rest of APAC by Country/Region, 2021-2031, $ mn 91

Table 30. Breakdown of World Market by Key Vendor, 2021, % 94

Table 31. Approved and Launched MRD Testing Products of Key Vendors 94

Table 32. Adaptive Biotechnologies Corporation: Company Snapshot 97

Table 33. Adaptive Biotechnologies Corporation: Business Segmentation 98

Table 34. Adaptive Biotechnologies Corporation: Product Portfolio 98

 

 

 

 

 

List of Figures:

 

Figure 1. Research Method Flow Chart 11

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14

Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16

Figure 4. Asia Pacific Minimal Residual Disease Testing Market, 2021-2031, $ mn 19

Figure 5. Impact of COVID-19 on Business 22

Figure 6. Primary Drivers and Impact Factors of Asia Pacific Minimal Residual Disease Testing Market 24

Figure 7.  World Number of Deaths from Cancers in 201 27

Figure 8.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28

Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 28

Figure 10. Primary Restraints and Impact Factors of Asia Pacific Minimal Residual Disease Testing Market 30

Figure 11. Investment Opportunity Analysis 34

Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Minimal Residual Disease Testing Market 37

Figure 13. Breakdown of Asia Pacific Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue 42

Figure 14. Asia Pacific Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%) 42

Figure 15. Asia Pacific Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn 43

Figure 16. Asia Pacific Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn 44

Figure 17. Breakdown of Asia Pacific Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue 46

Figure 18. Asia Pacific Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 46

Figure 19. Asia Pacific Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn 47

Figure 20. Asia Pacific Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn 49

Figure 21. Asia Pacific Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn 50

Figure 22. Asia Pacific Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn 51

Figure 23. Asia Pacific Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn 52

Figure 24. Asia Pacific Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn 53

Figure 25. Asia Pacific Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn 54

Figure 26. Asia Pacific Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn 55

Figure 27. Asia Pacific Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn 56

Figure 28. Asia Pacific Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn 57

Figure 29. Asia Pacific Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn 58

Figure 30. Asia Pacific Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn 59

Figure 31. Asia Pacific Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn 60

Figure 32. Asia Pacific Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn 61

Figure 33. Asia Pacific Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn 62

Figure 34. Breakdown of Asia Pacific Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue 64

Figure 35. Asia Pacific Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 64

Figure 36. Asia Pacific Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn 65

Figure 37. Asia Pacific Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 66

Figure 38. Asia Pacific Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn 67

Figure 39. Asia Pacific Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn 68

Figure 40. Breakdown of Asia Pacific Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue 70

Figure 41. Asia Pacific Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 70

Figure 42. Asia Pacific Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn 71

Figure 43. Asia Pacific Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn 72

Figure 44. Asia Pacific Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 73

Figure 45. Asia Pacific Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn 74

Figure 46. Breakdown of APAC Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 76

Figure 47. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 77

Figure 48.  Minimal Residual Disease Testing Market in Japan, 2021-2031, $ mn 79

Figure 49.  Minimal Residual Disease Testing Market in China, 2021-2031, $ mn 81

Figure 50.  Minimal Residual Disease Testing Market in Australia, 2021-2031, $ mn 83

Figure 51.  Minimal Residual Disease Testing Market in India, 2021-2031, $ mn 86

Figure 52.  Minimal Residual Disease Testing Market in South Korea, 2021-2031, $ mn 88

Figure 53.  Minimal Residual Disease Testing Market in Rest of APAC, 2021-2031, $ mn 90

Figure 54. Growth Stage of Asia Pacific Minimal Residual Disease Testing Industry over the Forecast Period 92